Health Care/Hospital

ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization

BASEL, Switzerland, March 30, 2023 /PRNewswire/ -- ACROBiosystems has begun to narrow its focus into helping accelerate the process between preclinical, clinical and commercialization. With over 10 years development, ACROBiosystems continues to surprise and bring new solutions to the pharmaceutic...

2023-03-30 20:51 1743

Zhongchao Inc. Announces Launch of Health Education Intelligent Content Production Platform

SHANGHAI, March 30, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with cancer and other major diseases, today announced the launch of "E-Class," medical education intelligent content p...

2023-03-30 20:00 1488

Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the interna...

2023-03-30 20:00 2881

ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization

NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process. As such, ACROBiosystems has begun to narrow its ...

2023-03-30 18:54 1719

DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200

SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...

2023-03-30 17:39 1639

Zylox-Tonbridge Announces Financial Results for 2022: Revenue Increases by 87.8% YOY to RMB 334 million and Gross Profit Reaches RMB 253 million

HANGZHOU, China, March 30, 2023 /PRNewswire/ -- On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, hereinafter referred to as the "Company") released its annual financial results for 2022. During the reporting period, the Company's operating revenue increased by 87.8% YOY ...

2023-03-30 15:49 1899

Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023

Employees express trust in leaders' competence and integrity and value fairness and impartiality as part of the workplace culture SINGAPORE, March 30, 2023 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announced the 10 companies who are Best WorkplacesTM in its ...

2023-03-30 12:00 2197

USANA Ranked #1 Direct Selling Brand for Calcium Supplements in Hong Kong

Euromonitor International honors USANA Hong Kong HONG KONG, March 30, 2023 /PRNewswire/ -- USANA Hong Kong was recently recognized as a top brand for calcium supplements by market research giant Euromonitor International. This distinction is based on market research of USANA's MagneCal D supplem...

2023-03-30 10:49 2081

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...

2023-03-30 08:00 1535

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as ofMarch 29, 2023, the company has conducted 13 clinical studies cover...

2023-03-30 08:00 2214

Zimmer Biomet's ROSA HIP with ONE Planner Hip Awarded Orthopaedic Product Innovation of the Year by Healthcare Asia Medtech Awards 2023

SINGAPORE , March 30, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that ROSA HIP ® with ONE Planner™ Hip won the "Orthopaedic Product Innovation of the Year" at this year's Healthcare Asia Medtech Awards. As a precise...

2023-03-30 08:00 2832

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

 - ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease - LOS ANGELES, March 30, 2023 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology ...

2023-03-30 03:32 2305

Broncus Medical (02216.HK) Announces Annual Results for 2022

Product sales in China for 2022 increased 50% compared to the same period in 2021, while product development and commercialization are steadily advancing. HANGZHOU, China, March 30, 2023 /PRNewswire/ -- On March 29, 2023, Broncus Medical (02216.HK), a leader in precise interventional diagnosis an...

2023-03-30 01:05 2990

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

GUANGZHOU, China, March 29, 2023 /PRNewswire/ -- The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit toChina. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, Health Mini...

2023-03-29 22:53 2771

LifeTech Reports Steady Growth of 32.5percent in Net Profit Attributable to Owners of the Company in 2022

SHENZHEN, China, March 29, 2023 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "Lifetech"), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced its 2022 annual results. ...

2023-03-29 22:21 2766

bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases

-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku,Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-k...

2023-03-29 22:00 1814

CHINA LIFE INSURANCE COMPANY LIMITED ANNOUNCES 2022 ANNUAL RESULTS (H SHARES)

HONG KONG, March 29, 2023 /PRNewswire/ -- China Life Insurance Company Limited (SSE: 601628, SEHK: 2628) announces the audited consolidated results of the Company (China Life Insurance Company Limited and its subsidiaries) for the year ended31 December 2022 (the "Reporting Period") prepared under...

2023-03-29 21:22 2407

Scivita Medical enters into Strategic Agreement with Boston Scientific in China

SUZHOU, China, March 29, 2023 /PRNewswire/ -- Medical technology company Scivita Medical Technology Co., Ltd. ('Scivita Medical') and Boston Scientific (NYSE: BSX), one of the leading medical technology companies worldwide, have officially signed aStrategic Agreement for Scivita's Single-Use Perc...

2023-03-29 21:08 1407

Just Three Months Into 2023, United Imaging Says Four New Scanners in Multiple Imaging Modalities Are Now Commercially Available in the United States

The products expand the company's success in outpatient imaging and bring new benefits to the acute care and academic segments. HOUSTON, March 29, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, announced that four new sc...

2023-03-29 21:00 1217

HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth

* Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical business in Korea, supporting growth in domestic drug sales * Sean Jeong, who has been serving as Co-CEO since March 2021, will continue to lead HanAll's R&D, including its subsidiary HanAll Pharmace...

2023-03-29 19:00 1276
1 ... 175176177178179180181 ... 807